Skip to Content
  • Title
  • Company
    Novo Nordisk

The world’s largest insulin maker has stuck with a big bet on diabetes, which has meant huge margins as the disease exacts an ever-widening toll. During Sorensen’s 16 years as CEO, he consistently delivered healthy growth, with revenues five times as big as when he took the helm and profits reaching a record $5.6 billion (on $16.7 billion in sales) in the past 12 months. Now, though, Novo Nordisk faces pricing pressures and Sorenson will retire at year’s end.

Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now